Tenax Therapeutics closed at $13.45 on Friday. It opened Monday at $1.77. In between, the company’s only Phase 3 trial reported a treatment difference of 3.5 meters on its primary endpoint, a result so far from significance that seven Wall Street analysts cut their price targets by roughly 90% apiece within a single trading day.
Tenax’s Phase 3 LEVEL Trial Misses Primary and Key Secondary Endpoints
Tenax Therapeutics (Nasdaq: TENX) announced topline results on August 10 from the Phase 3 LEVEL trial of TNX-103, an oral formulation of levosimendan, in pulmonary hypertension due to heart failure with preserved ejection fraction, a disease with no FDA-approved therapy. The randomized, double-blind, placebo-controlled trial enrolled 241 patients across 41 sites in the United States and Canada. The trial did not meet its primary endpoint, improvement in 6-minute walk distance at week 12, with a treatment difference of just 3.5 meters versus placebo and a p-value of 0.63, far short of statistical significance. The key secondary endpoint, change in Kansas City Cardiomyopathy Questionnaire total symptom score, also failed to separate from placebo.
Safety data offered little consolation but also no new alarm: serious adverse events occurred at nearly identical rates between the treatment and placebo arms (10.8% versus 10.7%), and adjudicated clinical worsening events were balanced across groups. Overall adverse event rates ran somewhat higher on TNX-103 than placebo. Levosimendan itself is not a new molecule; it already holds market authorization in 60 countries as an intravenous treatment for acutely decompensated heart failure, though it has never been available in the US or Canada in any form.
A Subgroup Analysis Offers a Narrower Path Forward
Tenax’s own framing is that the trial’s broad entry criteria diluted the result. In a prespecified subgroup of patients who walked less than the trial’s median distance of 333 meters at baseline, the sicker half of the study population, TNX-103 improved walk distance by 26.3 meters versus placebo, with a 95% confidence interval of 6.0 to 46.7 meters. That result was corroborated by a 49% reduction in NT-proBNP, a cardiac biomarker, and a 3.5 mmHg reduction in right ventricular systolic pressure, both nominally significant. Sanjiv Shah, the trial’s principal investigator and director of the HFpEF program at Northwestern University’s Feinberg School of Medicine, said in a statement that a drug producing this kind of effect on cardiac structure and function is likely disease-modifying, even though the overall population result wasn’t statistically significant.
The distinction matters because a prespecified subgroup finding, agreed upon before unblinding, carries more regulatory weight than a post-hoc observation, but it is still not the same as a trial that hits its primary endpoint outright. Nothing here is a formal efficacy finding for the broader PH-HFpEF population Tenax originally set out to treat.
Wall Street Slashes Price Targets as the Stock Craters
The market’s reaction was immediate and severe. Tenax shares fell from a Friday close of $13.45 to an intraday low near $1.31 on Monday, a decline of roughly 90%, before settling in the $1.50 to $1.65 range. Multiple sell-side firms slashed price targets within 24 hours of the announcement: Canaccord cut its target to $4 from $35, Guggenheim to $4 from $40, and Leerink to $4 from $26, while Evercore ISI and William Blair both downgraded the stock. Some of those same firms had set targets as high as $50 in the weeks before the data readout, a reminder of how binary a single-asset clinical-stage biotech’s valuation can be.
Tenax’s global rights to levosimendan for this indication are licensed from Orion Corporation, a Finnish pharmaceutical company; Orion disclosed the topline results as part of its own earnings reporting the same day. Analyst sentiment before the readout had been broadly bullish, with a consensus rating in the range of Buy to Strong Buy, which made the scale of Monday’s reversal more pronounced than it might have been for a stock that was already priced for a mixed outcome.
Tenax Plans FDA Type C Meeting to Discuss a Narrower Registrational Path
Tenax said it intends to request a Type C meeting with the FDA to discuss revisions to the ongoing registrational development of levosimendan for PH-HFpEF, and to seek parallel scientific consultation from the European Medicines Agency. No date for that meeting has been announced. Whether the FDA is willing to consider a registrational path built around the sicker-patient subgroup, rather than the broad population the LEVEL trial was originally powered for, is the open question that will determine whether TNX-103 has a future at all.
Sources
- Tenax Therapeutics / StockTitan 8-K filing: Tenax Therapeutics Reports Material Event, August 10, 2026
- BioSpace: Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF did not reach its primary endpoint, August 10, 2026
- HCPLive: TNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial, August 11, 2026
- Stocktwits: TENX stock price and news, August 10-11, 2026
- CNN Markets: Tenax Therapeutics (TENX) stock quote, analyst rating actions, August 10-11, 2026
Editorial Disclosure
This article is based entirely on publicly available information including company SEC filings, press releases, and contemporaneous news coverage. The security discussed is Tenax Therapeutics, Inc. (Nasdaq: TENX). aktiego.com has not received any compensation from Tenax Therapeutics, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication. The Phase 3 LEVEL trial did not meet its primary endpoint (6-minute walk distance, p=0.63) or its key secondary endpoint (KCCQ total symptom score); this miss is disclosed prominently and is not subordinated to the subgroup finding described later in this article. The subgroup analysis showing a 26.3-meter improvement was prespecified before unblinding, per Tenax’s disclosure, but a prespecified subgroup finding following a primary endpoint miss is not equivalent to a successful pivotal trial and does not by itself support an efficacy claim for the general PH-HFpEF population. The p-values associated with the subgroup, NT-proBNP, and right ventricular systolic pressure findings are described by Tenax as nominal, meaning they were not adjusted for multiple comparisons and carry a higher risk of false positive than a formally powered primary analysis. TNX-103 remains investigational and has not been approved by the FDA or any other regulatory agency for PH-HFpEF. Levosimendan’s approval in 60 countries applies to a different formulation (intravenous) and a different indication (acutely decompensated heart failure) and does not indicate or guarantee any future approval of TNX-103 in PH-HFpEF. Analyst price target and rating changes cited are hyperlinked to their aggregated source; aktiego.com does not independently verify third-party analyst research or price targets. No production, revenue, or regulatory approval should be assumed from the planned FDA Type C meeting, which is a request for a discussion, not a guarantee the agency will grant it or agree with any proposed path forward. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER
